Flex-nucleoside analogues, novel therapeutics against filoviruses and flaviviruses

Abstract

The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting flaviviruses, filoviruses and/or coronaviruses.

Claims

1. A method of treating and/or reducing the effects of a filovirus, flavivirus or coronavirus in a subject in need of such treatment, the method comprising administering to the subject therapeutically effective amount of an acyclic fleximer nucleoside analogue selected from the group consisting of: ##STR00005## and a pharmaceutically acceptable salt, isomer, hydrate, prodrug or solvate thereof.

2. The method of claim 1, wherein the acyclic fleximer nucleoside analogue is structure 9 and the coronavirus is severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS).

3. The method of claim 1, wherein the acyclic fleximer nucleoside analogue is structure 9 and the Flavivirus is Dengue, Zika or West Nile.

4. The method of claim 1, wherein the acyclic fleximer nucleoside analogue is structure 3 and the Filovirus is Ebola, Sudan or and Marburg.

5. The method of claim 1, wherein the acyclic fleximer nucleoside analogue is in a composition further comprising a pharmaceutically acceptable carrier.

6. The method of claim 5, wherein the acyclic fleximer nucleoside analogue is in a composition further comprising an additional antiviral agent.

7. The method of claim 1, wherein the therapeutically effective amount of the acyclic fleximer nucleoside analogue is from 0.05 to 50 mg per kilogram body weight of the subject per day.

8. A method of binding to natural and/or mutated polymerases of a filovirus, flavivirus or coronavirus in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of an acyclic fleximer nucleoside analogue selected from the group consisting of: ##STR00006## and a pharmaceutically acceptable salt, isomer, hydrate, prodrug or solvate thereof.

Description

BRIEF DESCRIPTION OF THE FIGURES

(1) FIG. 1 shows the structures of the target flexible nucleoside analogues of the present invention.

(2) FIG. 2 shows the dose response of Control compound E864 for treatment of (A) EBOV, (B) MARV and (C) SUDV.

(3) FIG. 3A shows the percentage inhibition (% INH) and FIG. 3B shows percent viability for compounds HP105 and MR064 for inhibition of EBOV in Hela cells and FIG. 3C shows a table with results.

(4) FIG. 4A shows the percentage inhibition (% INH) and FIG. 4B shows percent viability for compounds HP083, HP105 and MR064 for inhibition of SUDV in Hela cells and FIG. 4C shows a table with results.

(5) FIG. 5A shows the percentage inhibition (% INH) and FIG. 5B shows percent viability for compounds HP083, HP105 and MR064 for inhibition of MARV in Hela cells and FIG. 5C shows a table with results.

(6) FIG. 6 shows MTase activity for multiple viruses using sinefungin as a control and comparing to compounds 2MR04, MR064, HP105 and HP083.

(7) FIG. 7 shows MTase activity for multiple viruses using sinefungin as a control and comparing to compounds 2MR04, MR064, HP105 and HP083.

(8) FIG. 8 shows MTase activity for multiple viruses using the 2MR04 compound.

(9) FIG. 9 shows MTase activity for ZIKA virus using compounds 2MR04, MR064 and HP105.

(10) FIG. 10 shows MTase activity for Dengue virus using compounds 2MR04, MR064 and HP105.

(11) FIG. 11 shows test results using different viral inhibitors, compared to NTPs as a control, in the testing of MERS.

(12) FIG. 12 shows test results using different viral inhibitors, compared to NTPs as a control, in the testing of SARS-CoV.

(13) FIG. 13 shows blots of formation of nucleotide sequences using the 2MR04 inhibitor against MERS, SEQ ID NO 1.

(14) FIG. 14 shows blots of formation of nucleotide sequences using the 2MR04 inhibitor against SARS, SEQ ID NO. 1.

(15) FIG. 15 shows the effect of 2MR04 on Zika Virus.

DETAILED DESCRIPTION OF THE INVENTION

(16) Unique nucleoside analogues have been termed ‘fleximers’ and were designed to explore how nucleobase flexibility affects the recognition, binding, and activity of nucleoside(tide) analogues. The fleximers possess a purine base scaffold in which the pyrimidine moiety is attached by a single carbon-carbon bond, rather than being ‘fused’ as is typical for the purines. These analogues are designed to retain all of the requisite purine hydrogen bonding patterns while allowing the nucleobase to explore alternative binding modes.

(17) The present invention provides for a series of doubly flexible nucleoside analogues based on the acyclic sugar scaffold of acyclovir and the flex-base moiety found in the fleximers. The target compounds were evaluated for their antiviral potential and found to inhibit filoviruses, flaviviruses or coronaviruses.

(18) Mammal or human hosts infected with a filovirus, flavivirus or coronavirus can be treated by administering to said mammal or human an effective amount of an acyclic fleximer nucleoside analogue of the present invention and such compounds can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.

(19) The present invention relates to a method for treating a filoviral, flaviviral or coronaviral infection, comprising the administration, to a patient, of an effective amount of at least one acyclic fleximer nucleoside analogue of the present invention and/or of a composition containing same. In general, the acyclic fleximer nucleoside analogues, as active agents, of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. The effective amount will be that amount of an acyclic fleximer nucleoside analogue of the present invention that would be understood by one skilled in the art to provide therapeutic benefits. The active agent can be administered once a week, twice or more times per week, once a day, or more than once a day. As indicated above, all of the factors to be considered in determining the effective amount will be well within the skill of the attending clinician or other health care professional.

(20) For example, therapeutically effective amounts of an acyclic fleximer nucleoside analogue of the present invention may range from approximately 0.05 to 50 mg per kilogram body weight of the subject per day; preferably about 0.1-25 mg/kg/day, more preferably from about 0.5 to 10 mg/kg/day. Thus, for administration to a 70 kg person, the dosage range would most preferably be about 35-700 mg per day.

(21) In general, an acyclic fleximer nucleoside analogue of the present invention can be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.

(22) The choice of formulation depends on various factors such as the mode of drug administration and bioavailability of the acyclic fleximer nucleoside analogue. For delivery via inhalation the compound can be formulated as liquid solution, suspensions, aerosol propellants or dry powder and loaded into a suitable dispenser for administration.

(23) A composition comprising an acyclic fleximer nucleoside analogue of the present invention may be combined with at least one pharmaceutically acceptable carrier, excipient or diluent. Some examples of acceptable excipients are those that are non-toxic, will aid administration, and do not adversely affect the therapeutic benefit of the compound of the invention. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

(24) Solid pharmaceutical excipients useful in the invention may include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols. Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990). The amount of an acyclic fleximer nucleoside analogue of the present invention can vary within the full range employed by those skilled in the art. For example, a composition may contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of an acyclic fleximer nucleoside analogue of the present invention based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.

(25) The pharmaceutical composition according to the invention preferably comprises an amount of an acyclic fleximer nucleoside analogue of the present invention of between 5 μg and 1000 mg, preferably between 1 and 500 mg, preferably between 5 and 100 mg. The ratio between the amounts by weight of an acyclic fleximer nucleoside analogue of the present invention and of pharmaceutically acceptable carrier is between 5/95 and 95/5, preferably between 20/80 and 80/20.

(26) The acyclic fleximer nucleoside analogues of the present invention may be the only active ingredients, or they may be combined with other active ingredients. The pharmaceutical composition according to the invention may thus also comprise at least one other pharmaceutical active agent, in particular at least one other medicament used for the treatment of viral infection. In particular, the composition according to the invention may also comprise, or be combined with, one or more other antivirals. Generally, any antiretroviral may be combined, namely nucleoside or nucleotide and non-nucleoside inhibitors, protease inhibitors, entry inhibitors, etc.

(27) The acyclic fleximer nucleoside analogues of the present invention or compositions comprising same may be administered in various ways and in various forms. Thus, they may be administered systemically, orally, by inhalation or by injection, for instance intravenously, intramuscularly, subcutaneously, transdermally, intra-arterially, etc., intravenous, intramuscular, subcutaneous and oral administration. For the injections, the acyclic fleximer nucleoside analogues of the present invention are generally conditioned in the form of liquid suspensions, which can be injected by means of syringes or infusions, for example. In this regard, the acyclic fleximer nucleoside analogues of the present invention are generally dissolved in buffered, isotonic, physiological, saline, etc., solutions which are compatible with pharmaceutical use and known to those skilled in the art. Thus, the compositions may contain one or more agents or carriers chosen from dispersants, solubilizing agents, stabilizers, preservatives, etc. Agents or carriers which can be used in liquid and/or injectable formulations are, in particular, methylcellulose, hydroxymethylcellulose, carboxymethylcellulose, polysorbate 80, mannitol, gelatin, lactose, vegetable oils, acacia, etc.

(28) The acyclic fleximer nucleoside analogues of the present invention can also be administered in the form of gels, oils, tablets, suppositories, powders, gel capsules, capsules, aerosols, etc. For this type of formulation, an agent such as cellulose, carbonates or starches is advantageously used.

(29) Generally, for the purpose of the present invention, solvates of pharmaceutically acceptable solvents such as water and ethanol are equivalent to those not in forms of solvates.

(30) The present invention relates to a method for treating a viral infection, comprising the administration, to a patient, of an effective amount of at least one acyclic fleximer nucleoside analogue of the present invention and/or of a composition containing same. The acyclic fleximer nucleoside analogue can further be prodrugs or in form of capable of releasing the active ingredient after in vivo metabolism.

(31) Since the first reported fatal outbreak in the mid 1970s, members of the Filoviridae virus family, including the Ebola virus (EBOV), the Sudan virus (SUDV), and the Marburg virus (MARV), have continued to devastate many areas across the globe, with mortality rates as high as 90%.(1,2) One of the worst outbreaks of EBOV occurred in West Africa from 2013 to 2016, with over 28,000 documented infections and claiming more than 11,000 lives, including nearly 900 health care workers.(1) Filoviruses are a group of enveloped, single-stranded, negative-sense RNA viruses that cause fatigue, vomiting, and severe hemorrhagic fevers.(1,3,4) Members of the Filoviridae family are zoonotic viruses, where the primary reservoir is speculated to be fruit bats, however, it is unclear if this is the only reservoir or how the transmission to humans occurs.(2) The filoviruses are highly contagious and can easily spread through interaction with an infected individual by direct contact with bodily fluids including vomit, sweat, saliva, and respiratory secretions.2,4 With the high potential for re-emergence of these lethal viruses, particularly due to “super-spreaders”,(5,6) It is imperative that a viable treatment option be identified in order to better fight these crippling pathogens before the next outbreak occurs.

(32) While various therapeutic options have been pursued including vaccines,(7) monoclonal antibodies,(4,8) and recombinant proteins, (9,10) many of these have yet to reach clinical trials and may ultimately not translate well to effective treatments that can be made readily available during an outbreak, particularly in suboptimal conditions.(11)

(33) The present invention provides a therapeutic option using the nucleoside analogues as shown in FIG. 1. Nucleoside analogues have long been the cornerstone of antiviral therapies due to their ability to inhibit viral replication because they mimic the structure of the natural nucleosides.(12,13) As such, they can be recognized by cellular or viral enzymes, including the viral DNA or RNA polymerases. Moreover, because they contain various structural modifications, this leads to cessation of viral replication, typically due to chain termination.(13) Various nucleoside analogues against filoviruses such as EBOV have already been proposed including S-adenosylhomocysteine hydrolase (SAHase) inhibitors c3Ado and c3Nep (14,15) and the monophosphate derivative of BCX4430,(16) an adenosine analogue that acts as a non-obligate chain terminator, however, none of these have progressed to the clinic. Most recently GS-5734, a monophosphoramidate prodrug adenosine analogue which targets EBOV RNA-dependent RNA polymerase (RdRp), exhibited very potent activity against both EBOV and MARV,(17,18) further demonstrating the potential for finding effective nucleoside inhibitors of filoviruses. Over the past several years, research by the present inventor has focused on the development of flexible nucleoside analogues, termed “Fleximers”.(19-26)

(34) Herein, the anti-filovirus activity is reported for the analogues in FIG. 1, as well as the corresponding phosphoramidate prodrug 3.

(35) The synthesis of the target compounds began with the substituted imidazole 4, utilizing the routes previously employed in our group (Scheme 1).(26)

(36) ##STR00003##

(37) Treatment with sodium sulfite in a 30% ethanol/water solution resulted in simultaneous deacetylation and selective deiodination to provide key intermediate 5. Acetylation of 5 then generated 6, the 5′ protected intermediate needed for the prodrug synthesis. In parallel, the organometallic coupling reagent 7 was synthesized starting from the commercially available 2-amino-4-methoxypyrimidine.(27,28) Stille coupling of 7 to 5 gave 1. Alternatively, using the acetylated 6, Stille coupling provided the desired double prodrug 2.

(38) Synthesis of the McGuigan ProTide (29-33) started with commercially available L-alanine and utilized literature procedures to generate the phosphoramidate 8 (Scheme 2).(34) Reaction of 8 with fleximer 1 in the presence of tert-butyl magnesium chloride then provided the desired McGuigan ProTide 3 in 69% yield.

(39) ##STR00004##

(40) After the successful synthesis of the three Flex-analogues 1, 2, and 3, the compounds were screened against a panel of filoviruses including EBOV, MARV, and SUDV, as well as other hemorrhagic fever viruses such as Lassa and Rift Valley Fever. The first series of assays utilized HeLa cells infected with live-virus isolates of EBOV (Makona), SUDV (Gulu), and MARV (Ci67). Activity against all three viruses was observed for the McGuigan prodrug 3, with the best activity against SUDV (Table 1).

(41) The second series of assays utilized Huh7 cells infected with recombinant reporter EBOV, Lassa, and Rift Valley Fever viruses. As observed in the first series of assays, compound 3 was active against EBOV at a similar concentration, however, compound 1 exhibited the best activity (EC.sub.50=2.2±0.3 lM) against EBOV in Huh7 cells (Table 2).

(42) TABLE-US-00001 TABLE 1 Antiviral activity of nucleoside analogues in infected HeLa cells, values are in 1M. EBOV SUDV MARV CMPD EC.sub.50 CC.sub.50 EC.sub.50 CC.sub.50 EC.sub.50 CC.sub.50 1 >100 >100 >100 >100 >100 >100 2 44 ± 13 >100 20 ± 10 >100 70 ± 27 >100 3 29 ± 9  >100 7 ± 2 >100 62 ± 13 >100 EC.sub.50: Effective concentration showing 50% inhibition of virus-induced Cytopathic effect CPE CC.sub.50: Cytotoxic concentration showing 50% inhibition of cell survival

(43) TABLE-US-00002 TABLE 2 Antiviral activity of nucleoside analogues against recombinant reporter viruses in Huh7 cells in 1M. EBOV Lassa Virus Rift Valley Fever CMPD EC.sub.50 CC.sub.50 EC.sub.50 CC.sub.50 EC.sub.50 CC.sub.50 1 2.2 ± 0.3 >50 >50 >50 >50 >50 3 27.2 ± 2.2  >50 >50 >50 >50 >50 EC.sub.50: Effective concentration showing 50% inhibition of virus-induced Cytopathic effect CPE CC.sub.50: Cytotoxic concentration showing 50% inhibition of cell survival

(44) Infectious diseases such as EBOV continue to pose a serious health threat due to the high mortality rates associated with these deadly viruses. While ongoing studies have identified various therapeutics as potential EBOV treatments, there are limited vaccines or therapeutics available, and as such, it is imperative that an effective treatment option is developed. Within this study it was found that both compounds 1 and 3 exhibited antiviral activity against a recombinant reporter EBOV in Huh7 cells, though surprisingly the McGuigan prodrug was ˜10-fold less potent (EC.sub.50=2.2±0.3 lM and 27.2±2.2 lM respectively). Against wild-type viruses in HeLa cells, compound 1 had no detectable activity, though compound 3 inhibited both EBOV and SUDV (EC.sub.50=29±9 and 7±2 lM respectively). The difference in activity of 1 in the Huh7 cells compared to the HeLa cells is most likely due to a difference in specific metabolism of the compound in those cells lines.

(45) Three compounds in Table 3 were tested in Ebola/Makona (except Hp083), Ebola/Sudan and Marburg infection assay with HeLa, and HFF cell lines. Stock solutions were made at 10 mM in 100% DMSO. Compounds were dispensed 2 h before infection by HP D300 directly from the 100% DMSO stock into assay wells with cells. DMSO was normalized in all wells to final 1%. Compound activity was tested in a 8-point dose response with 3 fold step dilution (see table below). The titration started at 100 μM (final) and repeated 3 times on a single plate (n=3).

(46) TABLE-US-00003 TABLE 3 1 2 3 4 5 6 7 8 HP105 100 33.33 11.11 3.70 1.23 0.41 0.14 0.05 MR064 100 33.33 11.11 3.70 1.23 0.41 0.14 0.05 HP083 100 33.33 11.11 3.70 1.23 0.41 0.14 0.05

(47) 16 wells were treated with 1% DMSO to be used as a neutral control. Additionally, 16 wells were not infected and were used as a low signal controls. Cells were infected with EBOV(Makon) in Hela with Multiplicity Of Infection (MOI)=1.5, Marburg (Ci-67) MOI=1.0 and Sudan (Gulu) MOI=0.1. Infection was stopped after 48 h by fixing cells with a formalin solution.

(48) To detect infected cells an immuno-staining was completed with anti-GP antibodies. Images were acquired by the PE Opera confocal platform using a 10× objective and were analyzed using Acapella software. Signal for GP-staining was converted into % infection. The number of nuclei per well was used to determine % viability of cells (in comparison to infected but untreated controls). Data was analyzed using GeneData software. % of infection was converted into % Inhibition (% INH) for each well using plate controls.

(49) FIG. 2 shows the plates statistics for the three different viruses indicating the level of infection and number of nuclei. Also included are three graphs showing the use of a control compound E864 on the three different viruses.

(50) FIGS. 3, 4 and 5 show that one of the tested nucleosides, that being nucleoside 3, demonstrated highest antiviral activity in Hela cells against EBOV (EC.sub.50 29.10), SUDV (EC.sub.50 6.85) and MARV (EC.sub.50 62.29).

(51) A number of flaviviruses cause human disease, particularly hemorrhagic fevers and encephalitis. Each species of flavivirus has a unique geographic distribution; however, taken together, flaviviruses, and flavivirus-induced disease, can be found world-wide. One of the more commonly known diseases is dengue fever, or dengue hemorrhagic fever/shock, which was first described as a virus-induced illness in 1960. Dengue fever occurs in tropical and temperate climates—and is spread by Aedes mosquitoes. The symptoms include febrile headache, joint pain, rash, capillary leakage, hemorrhage and shock. Another common flavivirus-induced disease is yellow fever. Yellow fever is found in tropical Africa and America and is transmitted by mosquitoes. The mortality rate is approximately 30% and symptoms include febrile headache, myalgia (muscle pain), vomiting and jaundice. Examples of some of the other diseases caused by flavivirus species include Japanese encephalitis, and West Nile fever. These diseases share many of the same symptoms, which may include headache, myalgia, fever, hemorrhage, encephalitis, paralysis and rash.

(52) Dengue virus (DV) is a mosquito-borne pathogen that causes dengue fever (DF) and severe life threatening illness, dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). DV is a small, enveloped, positive-stranded RNA virus that belongs to the Flavivirus genus of the Flaviviridae family which also includes Zika virus, and yellow fever virus. Zika virus (ZIKV) is an arthropod-borne Flavivirus and since 2015 has rapidly spread through South and Central America and the Caribbean. ZIKV was first discovered in Uganda in 1947 in the course of mosquito and primate surveillance. The infection, known as Zika fever, often causes no or only mild symptoms, and had until now remained a rare disorder confined within a narrow equatorial belt from Africa to Asia. The World Health Organization (WHO) has declared the Zika virus an international public health emergency, prompted by growing concern that an increased incidence of microcephaly in fetuses born to mothers infected with ZIKV is linked to the recent outbreaks.

(53) Additional testing was conducted on multiple types of viruses using compounds 2MR04, MR064, HP105 and HP083 and sinefungin as an inhibitory positive control. The compounds were solubilized in water (1 mM) with a final concentration of 50 μM. The following enzymes were used (independent triplicates, except for DV experiment performed induplicate): 1) SARS-CoV nsp14 (N7 MTase): 10 nM 2) MERS-CoV nsp14 (N7 MTase): 125 nM 3) MERS-CoV nsp10/nsp16 (2′O MTase): 500 nM 4) Zika virus NS5 MTase: 500 nM 5) Dengue virus NS5 MTase: 500 nM 6) hPMV CRIV+: 1 μM 7) human N7 MTase (hN7 or RNMT): 20 nM

(54) Methyltransferase (MTase) is involved in RNA capping process and important for mRNA stability, protein synthesis and also virus replication, thus MTase is an attractive target in designing MTase inhibitors. Sinefungin, a well-known anti-fungal AdoMet analogue and which is known to inhibit methylation and viral replication in other flaviviruses, thus, making MTase a valid target anti-virus drug discovery

(55) The results are shown in FIG. 6 for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), ZIKA, Dengue, hMPV (Human metapneumovirus), and RNMT (RNA Guanine-7 Methyltransferase). As can be seen, 2MR04 inhibits several MTase (SARS-nsp14, Dengue & Zika virus MTases as well as hMPV MTase) in contrast to the RNMT (RNA Guanine-7 Methyltransferase), which is not inhibited. In addition, it was observed that MR064 and HP-105 also inhibited Dengue virus NS5 MTase.

(56) Additional testing was conducted at 50 μM on other mononegavirus MTases (in triplicate): 1) human N7 MTase (hN7 or RNMT): 20 nM 2) hMPV MTase: 1 3) RSV MTase: 4 4) SUDV MTase: 4

(57) FIG. 7 shows that compound 2MR04 was effective in strongly inhibiting the MTase activity of hMPV and RSV (Respiratory syncytial virus), viruses belonging to the family Pneumoviridae. The IC.sub.50 values for 2MR04 was determined and shown in FIG. 8 wherein the IC.sub.50 for the hN7 MTase was about 49 μM, about 31 μM on hMPV, and about 18 μM for RSV.

(58) FIGS. 9 and 10 show the results for determining the IC.sub.50 for the Zika NS5-MTase and DV NS5-MTase using three compounds, that being, MR064, HP105 and 2MR04. It was found that 2MR04 strongly inhibits both the Zika NS5-MTase and DV NS5-MTase with an IC.sub.50 of about 22 μM. Also in FIG. 15, it is shown in another testing that 2 MR04 inhibited even stronger, that being, with an IC50 of about 17 μM.

(59) The fleximer 2MR04 was also tested for MERS and SARS-Cov. In vitro enzymatic assays were carried out in polymerase assay buffer (20 mM Hepes pH 7.5; 10 mM KCl; 10 mM DTT; 4 mM MgCl2) in case of MERS-Coronavirus and buffer (20 mM Tris pH 8; 10 mM KCl; 1 mM DTT; 2 mM MgCl.sub.2) in case of SARS-Coronavirus. For the reaction, 1 μM of MERS polymerase complex (12HC/7HC8) or 0.6 μM of SARS polymerase complex (12HC/7HC8) were mixed with 0.5 μM of a radiolabeled primer annealed to a template substrate and assembled at 30° C. for 30 min.

(60) The primer extension was started by the addition of either 50 μM of each potential inhibitor or 50 μM of each inhibitor plus 20 μM of a NTPs mix. After incubation at 30° C., aliquots of reactions were quenched at various time points by the addition of an equal volume of loading buffer (formamide with 10 mM EDTA). Reaction products were loaded onto 20% polyacrylamide/7M urea gels, visualized using a Phosphorlmager (Fuji), and quantified using ImageQuant Software (Fuji).

(61) As noted in FIG. 11, the inhibitor 2MR04 is as effective as the 3′ dGTP inhibitor (known as an N-pocket inhibitor) along with 2′-O-methyl GTP which is able to act as a chain terminator and inhibit RNA synthesis in the testing for MERS inhibitors. The percentage of product formed is greatly reduced relative to the control of 20 μM NTPs. In contrast. the results for the inhibitor 2MR04 were found to be comparable to the other inhibitors as shown in FIG. 12.

(62) FIG. 13 shows blots of products formed using the MERS inhibitors and it is evident that the inhibitor 2MR04 (alone or with NTPs) was as effective, not more effective, in reduction of oligonucleotide synthesis. Likewise FIG. 14 shows that using the SARS inhibitors that the inhibitor 2MR04 (alone or with NTPs) was as effective in reduction of oligonucleotide synthesis.

REFERENCES

(63) The contents of the references cited herein are incorporated by reference herein for all purposes. 1. Boisen M L, Hartnett J N, Goba A, et al. Annu Rev Virol. 2016; 3:147-171. 2. Moghadam S R J, Omidi N, Bayrami S, Moghadam S J, Seyed Alinaghi S. Asian Pac J Trop Biomed. 2015; 5:260-267. 3. Rougeron V, Feldmann H, Grard G, Becker S, Leroy E M. J Clin Virol. 2015; 64:111-119. 4. Mendoza E J, Qiu X, Kobinger G P. Trends Mol Med. 2016; 22:164-173. 5. Lau M S, Dalziel B D, Funk S, et al. Proc Natl Acad Sci USA. 2017; 114:2337-2342. 6. L. H. Sun, Disease ‘superspreaders’ accounted for nearly two-thirds of Ebola cases, study finds, www.washingtonpost.com/news/to-your-health/wp/2017/02/13/disease-superspreaders-accounted-for-nearly-two-thirds-of-ebolacases-study-finds/?utm_term=.555a3aacb28a, (accessed Mar. 20, 2017, 2017). 7. Mire C E, Geisbert T W, Feldmann H, Marzi A. Expert Rev Vaccines. 2016; 15:1421-1430. 8. Qiu X, Audet J, Wong G, et al. Sci Transl Med. 2012; 4.138ra181. 9. Geisbert T W, Hensley L E, Jahrling P B, et al. Lancet. 2003; 362:1953-1958. 10. Geisbert T W, Lee A C, Robbins M, et al. Lancet. 2010; 375:1896-1905. 11. Picazo E, Giordanetto F. Drug Discov Today. 2015; 20:277-286. 12. De Clercq E. Nat Rev Microbiol. 2004; 2:704-720. 13. De Clercq E, Neyts J. Handb Exp Pharmacol. 2009; 53-84. 14. Huggins J W, Zhang Z X, Monath T P. Antiviral Res. 1991; 15. 15. Coulombe R A, Sharma R P, Huggins J W. Eur J Drug Metab Pharmacokinet. 1995; 20:197-202. 16. Warren T K, Wells J, Panchal R G, et al. Nature. 2014; 508:402-405. 17. Warren T K, Jordan R, Lo M K, et al. Nature. 2016; 531:381-385. 18. Lo M K, Jordan R, Arvey A, et al. Sci Rep. 2017; 7:43395. 19. Seley K L, Zhang L, Hagos A. Org Lett. 2001; 3:3209-3210. 20. Seley K L, Zhang L, Hagos A, Quirk S. J Org Chem. 2002; 67:3365-3373. 21. Seley K L, Quirk S, Salim S, Zhang L, Hagos A. Bioorg Med Chem Lett. 2003; 13:1985-1988. 22. Polak M, Seley K L, Plavec J. J Am Chem Soc. 2004; 126:8159-8166. 23. Quirk S, Seley K L. Biochemistry. 2005; 44:13172-13178. 24. Quirk S, Seley K L. Biochemistry. 2005; 44:10854-10863. 25. Seley K L, Salim S, Zhang L, O'Daniel P I. J Org Chem. 2005; 70:1612-1619. 26. Peters H L, Jochmans D, de Wilde A H, et al. Bioorg Med Chem Lett. 2015; 25:2923-2926. 27. Minakawa N, Kojima N, Hikishima S, et al. J Am Chem Soc. 2003; 125:9970-9982. 28. Wauchope O R, Velasquez M, Seley-Radtke K. Synthesis (Stuttg). 2012; 44:3496-3504. 29. Mehellou Y, Balzarini J, McGuigan C. Chem Med Chem. 2009; 4:1779-1791. 30. Pertusati F, Serpi M, McGuigan C. Antivir Chem Chemother. 2012; 22:181-203. 31. Madela K, McGuigan C. Future Med Chem. 2012; 4:625-650. 32. Cahard D, McGuigan C, Balzarini J. Mini Rev Med Chem. 2004; 4:371-381. 33. Pradere U, Garnier-Amblard E C, Coats S J, Amblard F, Schinazi R F. Chem Rev. 2014; 114:9154-9218. 34. Ross B S, Reddy P G, Zhang H R, Rachakonda S, Sofia M J. J Org Chem. 2011; 76:8311-8319.